Myocardial stunning

disease

On this page

Summary

Myocardial stunning (MONDO:0004876) is a disease and 13 clinical trials. Top therapeutic interventions include cyanocobalamin, ranolazine, and levosimendan. A subtype of myocardial infarction — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

Clinical trials: 13

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	myocardial stunning
Mondo ID	MONDO:0004876
MeSH	D017682
DOID	DOID:9767
UMLS	C0206146
MedGen	61526
Is cancer (heuristic)	no

Disease family

This is a subtype of myocardial infarction. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › myocardial disorder › myocardial infarction › myocardial stunning

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 13.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	8
PHASE4	2
PHASE1	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01500785	PHASE4	TERMINATED	Intracoronary Administration of Levosimendan in Cardiac Surgery Patients
NCT02687269	PHASE4	WITHDRAWN	Ranolazine a Potential New Therapeutic Application
NCT05669144	PHASE1/PHASE2	UNKNOWN	Co-transplantation of Mesenchymal Stem Cell Derived Exosomes and Autologous Mitochondria for Patients Candidate for CABG Surgery
NCT04830982	PHASE1	WITHDRAWN	Safety and Efficacy of IV Diazoxide as an Additive to Hyperkalemic Cardioplegia in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass
NCT06308107	PHASE1	COMPLETED	Safety and Feasibility of Hyperkalemic Cardioplegia With Diazoxide in Cardiac Surgery (CPG-DZX) Trial
NCT04448639	Not specified	RECRUITING	Stunning in Takotsubo Versus Acute Myocardial Infarction
NCT00123695	Not specified	UNKNOWN	Serial Echocardiography After Subarachnoid Hemorrhage
NCT00213746	Not specified	COMPLETED	Evaluation of Myocardial Viability by Means of Low-dose Dobutamine Gated SPECT (the DOGS Study)
NCT01179802	Not specified	COMPLETED	Exercise-induced Changes in Cardiac Function & Morphology
NCT02545426	Not specified	COMPLETED	Myocardial Stunning During Hemodialysis: Role of Dialyste Calcium Concentration
NCT02770183	Not specified	WITHDRAWN	Rate of Left Ventricular Systolic Function’s Recuperation After Cardiac Surgery With Extracorporeal Circulation.
NCT05209230	Not specified	COMPLETED	Is Myocardial Stunning Induced by Continuous Renal Replacement Therapy a Reality in Critically Ill Patients?
NCT06450912	Not specified	COMPLETED	Novel Imaging Biomarkers for Mechanical Complications in Acute Myocardial Infarction

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CYANOCOBALAMIN	4	1
RANOLAZINE	4	1
LEVOSIMENDAN	3	1

Drugs: Cyanocobalamin, Ranolazine, Levosimendan